Biltmore Family Office’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
– Sell
-35
Closed -$896 – 267
2024
Q3
$896 Hold
35
– – ﹤0.01% 264
2024
Q2
$822 Hold
35
– – ﹤0.01% 243
2024
Q1
$1.01K Hold
35
– – ﹤0.01% 229
2023
Q4
$1.15K Hold
35
– – ﹤0.01% 224
2023
Q3
$975 Buy
+35
New +$1.14K ﹤0.01% 233

Other funds holding ARKG

Biltmore Family Office's ARKG Position: Q4 2024 in Review

Biltmore Family Office sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2024, closing a stake of 35 shares — an estimated $896 sold.

Biltmore Family Office first reported a position in ARKG in Q3 2023 and held it in 5 quarters. The position peaked at $1.15K in Q4 2023. 241 funds tracked by Wall St. Rank hold ARKG as of Q4 2024.

  • Biltmore Family Office reported no remaining ARK Genomic Revolution ETF position as of Q4 2024 after selling out during the quarter.
  • Biltmore Family Office sold 35 ARK Genomic Revolution ETF shares in Q4 2024, an estimated $896.
  • Biltmore Family Office first reported a position in ARK Genomic Revolution ETF in Q3 2023 and held it in 5 quarters.
  • Biltmore Family Office's ARK Genomic Revolution ETF position peaked at $1.15K in Q4 2023.
  • 241 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2024.

Based on Biltmore Family Office's 13F filing for Q4 2024, filed 12 Feb 2025.